Key Insights

Highlights

Success Rate

95% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 37/100

Termination Rate

4.8%

1 terminated out of 21 trials

Success Rate

94.7%

+8.2% vs benchmark

Late-Stage Pipeline

10%

2 trials in Phase 3/4

Results Transparency

50%

9 of 18 completed with results

Key Signals

9 with results95% success

Data Visualizations

Phase Distribution

20Total
Not Applicable (6)
P 1 (6)
P 2 (6)
P 3 (2)

Trial Status

Completed18
Terminated1
Active Not Recruiting1
Withdrawn1

Trial Success Rate

94.7%

Benchmark: 86.5%

Based on 18 completed trials

Clinical Trials (21)

Showing 20 of 20 trials
NCT01384513Phase 2Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

NCT01199562Active Not Recruiting

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

NCT01588015Phase 1Completed

Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant

NCT00489203Phase 2Completed

Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

NCT00856388Not ApplicableCompleted

Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders

NCT01305200Phase 3Completed

Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant

NCT01159067Phase 2Terminated

Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload

NCT01484015Phase 1Completed

Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia

NCT01053494Not ApplicableCompleted

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

NCT00112593Not ApplicableCompleted

Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer

NCT00795769Phase 2Completed

Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant

NCT00408681Not ApplicableCompleted

Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant

NCT00381550Phase 2Completed

3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia

NCT01231919Phase 1Completed

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

NCT01233921Not ApplicableCompleted

Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer

NCT00890747Phase 1Completed

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

NCT00357305Phase 1Completed

Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders

NCT00025415Phase 1Completed

Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction

NCT01558778Not ApplicableWithdrawn

Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant

NCT00799461Phase 3Completed

Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications

Scroll to load more

Research Network

Activity Timeline